Pediatric Lung Transplant Program, Washington University School of Medicine, St. Louis, MO, USA.
Transpl Int. 2013 Jul;26(7):696-703. doi: 10.1111/tri.12115. Epub 2013 May 23.
Strategies for induction in lung transplant recipients typically mirror those used in other solid organ transplant recipients. Polyclonal (Atgam, RATG) and monoclonal (OKT3) T-cell depleting agents, IL-2 Receptor antagonists (basiliximab and daclizumab) have been used most commonly. In spite of evidence from ISHLT registry reports that induction reduces acute rejection and has a small benefit in freedom from bronchiolitis obliterans and long-term survival, other studies have been less convincing in terms of long-term benefit. Future iterations of induction strategy for lung transplant recipients will hopefully utilize tolerogenic approaches currently being tested in renal transplantation.
肺移植受者的诱导策略通常与其他实体器官移植受者使用的策略相似。多克隆（Atgam、RATG）和单克隆（OKT3）T 细胞耗竭剂、白细胞介素-2 受体拮抗剂（巴利昔单抗和达利珠单抗）最常被使用。尽管 ISHLT 登记报告中的证据表明诱导可降低急性排斥反应，并可减少闭塞性细支气管炎和长期生存的获益，但其他研究在长期获益方面的说服力则较低。肺移植受者诱导策略的未来迭代有望利用目前正在肾移植中进行测试的耐受诱导方法。
